Quantcast
 
Learn to trade in these market conditions - Click here Just Released!


 

Ranbaxy introduces Omeprazole 40mg capsules

Tue. July 29, 2008; Posted: 11:26 AM
Stocks RSS
Jul 29, 2008 (Datamonitor via COMTEX) -- RBXLF | Quote | Chart | News | PowerRating -- Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories, Gurgaon, India, has announced that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorized generic of Omeprazole 40mg capsules in the US healthcare system.

Ranbaxy's Omeprazole 40mg is indicated for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome.

Jim Meehan, vice president of sales and distribution at Ranbaxy Pharmaceuticals, said: "We welcome the opportunity to market an authorized generic of Omeprazole 40mg capsules that will be commercialized immediately to all classes of trade in the US healthcare system under the Ranbaxy label.

"We will offer this product as an affordable and accessible generic formulation to patients requiring this medication."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

For full details for RBXLF click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [RBXLF]
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2008 The Connors Group, Inc.